Clinical Trial Update: Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C [Phase 4]

View source ↗

Summary

Phase 4 trial update on administering Zepatier (grazoprevir/elbasvir) in chronic hemodialysis patients with Hepatitis C; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemodialysis
• Hepatitis C

Drugs mentioned

• Zepatier (elbasvir/grazoprevir)

Snippet

Sponsor: University of Pennsylvania | Conditions: Hepatitis C, Hemodialysis | Phase 4 | Status: COMPLETED | Results posted: 2021-12-15